Boisdron-Celle M, Craipeau C, Brienza S, Delva R, Guerin-Meyer V, Cvitkovic E, Gamelin E.

Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences. Cancer Chemother Pharmacol. 2002 Mar; 49(3):235-43. Epub 2002 Jan 16.

Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E.

Cellular and molecular pharmacology of oxaliplatin. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Mol Cancer Ther. 2002 Jan; 1(3):227-35. Review.

Keating MJ, Cazin B, Coutre S, Birhiray R, Kovacsovics T, Langer W, Leber B, Maughan T, Rai K, Tjonnfjord G, Bekradda M, Itzhaki M, Herait P.

Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One prior Chemotherapy Regimen Has Failed. Journal of Clinical Oncology 20 (1): 205-213, 2002.

Gornet JM, Savier E, Lokiec F, Cvitkovic E, Misset JL, Goldwasser F.

Exacerbation of oxaliplatin neurosensory toxicity following surgery. Ann Oncol. 2002 Aug; 13(8):1315-8 .

Taamma A, Misset JL, Riofrio M, Guzman C, Brain E, Lopez Lazaro L, Rosing H, Jimeno JM, Cvitkovic E.

Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol. 2001 Mar 1;19(5):1256-65.

Louvet C, Andre T, Tigaud JM, Gamelin E, Douillard JY, Brunet R, Francois E, Jacob JH, Levoir D, Taamma A, Rougier P, Cvitkovic E, de Gramont A.

Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol. 2002 Dec 1; 20(23):4543-8.

Laurence V, Faivre S, Vera K, Pierga JY, Delbado C, Bekradda M, Armand JP, Gianella-Borradori A, Dieras V, Raymond E.

 Preliminary results of an ongoing phase I and pharmacokinetic study of CYC202, a novel cyclindependent kinases inhibitor, in patients with advanced malignancies. European Journal 38 (suppl 7): 49, 2002.

Cvitkovic E , Bekradda M, Essassi D, Beth Mardjetko M.

Antimicrotubule agents: Vindesine (Eldesine). Outline of Oncology Therapeutics: 24, 2001. Ratain, Tempero, Skosey. W.B Saunders Company [book chapter].

Cvitkovic E , Bekradda M, Essassi D, Noble-Kempin S.

DNA-binding agents: Oxaliplatin (Eloxatine). Outline of Oncology Therapeutics: 19, 2001. Ratain, Tempero, Skosey. W.B Saunders Company [book chapter].

Delaloge S, Yovine A, Taamma A, Riofrio M, Brain E, Raymond E, Cottu P, Goldwasser F, Jimeno J, Misset JL, Marty M, Cvitkovic E.

Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity. J Clin Oncol. 2001 Mar 1;19(5):1248-55.

Germa C, Bekradda M, Mignard D, Mousseau M.

 Randomized Multicenter Phase II Study Comparing a Combination of Fluorouracil and Folinic Acid and Alternating Irinotecan and Oxaliplatin With Oxaliplatin and Irinotecan in Fluorouracil-Pretreated Metastatic Colorectal Cancer Patients. Journal of Clinical Oncology 19 (22): 4195-4201, 2001.

Becouarn Y, Gamelin E, Coudert B, Negrier S, Pierga JY, Raoul JL, Provencal J, Rixe O, Krisch C,

2 3 4 5 6 7 8
Clikeo Agence Clikeo